A5083314734- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Bone health and treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Bone Metabolism and Diseases
- Ubiquitin and proteasome pathways
- Cancer, Hypoxia, and Metabolism
- Chemokine receptors and signaling
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Calcium signaling and nucleotide metabolism
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Cell Adhesion Molecules Research
- Protease and Inhibitor Mechanisms
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Blood Coagulation and Thrombosis Mechanisms
- Radiopharmaceutical Chemistry and Applications
- Angiogenesis and VEGF in Cancer
- Cytokine Signaling Pathways and Interactions
University of Parma
2016-2025
Ospedale di Parma
2016-2025
Free University of Bozen-Bolzano
2023-2024
Fondazione Gimema Onlus
2006-2020
Agenzia Sanitaria Regionale Abruzzo
2018
Casa Sollievo della Sofferenza
1996-2017
Istituti di Ricovero e Cura a Carattere Scientifico
1996-2017
Myeloma UK
2015-2016
Italian Society of Periodontology and Implantology
2015
Yorkshire Cancer Research
2014
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care elderly multiple myeloma patients. We assessed dosing, efficacy, safety lenalidomide (MPR) newly diagnosed patients.Oral melphalan was administered doses ranging from 0.18 to 0.25 mg/kg on days 1 4, prednisone at a 2-mg/kg dose 5 10 mg 21, every 28 for nine cycles, followed by maintenance therapy with alone. Aspirin given...
PURPOSE To evaluate the effect of bortezomib as induction therapy before autologous transplantation, followed by lenalidomide consolidation-maintenance in myeloma patients. PATIENTS AND METHODS Newly diagnosed patients age 65 to 75 years were eligible. Induction (bortezomib, doxorubicin, and dexamethasone [PAD]) included four 21-day cycles (1.3 mg/m(2) on days 1, 4, 8, 11), pegylated liposomal doxorubicin (30 day 4), (40 mg/d; cycle 1: 1 8 11, 15 18; 2 4: 4). Autologous transplantation was...
Multiple myeloma (MM) is a clonal plasma cell malignancy associated with osteolytic bone disease. Recently, the role of MM-derived exosomes in osteoclastogenesis has been demonstrated although underlying mechanism still unknown. Since exosomes-derived epidermal growth factor receptor ligands (EGFR) are involved tumor-associated osteolysis, we hypothesize that EGFR ligand amphiregulin (AREG) can be delivered by and participate MM-induced osteoclastogenesis. Exosomes were isolated from...
Human myeloma cells express CD38 at high levels and grow in hypoxic niches inside the bone marrow. Myeloma respond to hypoxia with metabolic changes leading aerobic glycolysis, thus reducing ATP increasing NAD+. Our hypothesis is that these conditions favor enzymatic pathways involved production of adenosine niche. Within niche, NAD+ able activate a discontinuous adenosinergic pathway relies upon CD38, CD203a, CD73 or TRACP, according environmental pH. The observed variability concentrations...
Abstract Myelodysplastic syndromes (MDS) are heterogeneous neoplastic disorders of hematopoietic stem cells (HSCs). The current standard care for patients with MDS is hypomethylating agent (HMA)-based therapy; however, almost 50% fail HMA therapy and progress to acute myeloid leukemia, facing a dismal prognosis due lack approved second-line treatment options. As cancer the seeds disease progression, we investigated biological properties HSCs that drive evolution, seeking uncover...